Crossmark

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Crossref DOI link: https://doi.org/10.1016/j.amjmed.2016.06.007

Published Print: 2016-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Reilly, Paul A.

van Ryn, Joanne

Grottke, Oliver

Glund, Stephan

Stangier, Joachim
Funding

Funding for this research was provided by:

Boehringer Ingelheim

Boehringer Ingelheim
License Information

Text and Data Mining valid from 2016-11-01

Text and Data Mining valid from 2016-11-01

Version of Record valid from 2016-09-13
More Information

This article is maintained by: Elsevier

Article Title: Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Journal Title: The American Journal of Medicine

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.amjmed.2016.06.007

Content Type: article

Copyright: © 2016 Published by Elsevier Inc.

Document is current

Any future updates will be listed below